Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1R ) and receptor-5 (S1P5R ) agonist with autoimmune disease-modifying activity.
Daclizumab (anti-CD25) in multiple sclerosis.
[The influence of locomotor treatment using robotic body-weight-supported treadmill training on rehabilitation outcome of patients suffering from neurological disorders].
Positive year one results from Biogen Idec's Phase 3 advance trial of PLEGRIDY™ (peginterferon beta-1a) presented at AAN meeting
Stress Management and Multiple Sclerosis: A Randomized Controlled Trial.
Fine-Mapping the Genetic Association of the Major Histocompatibility Complex in Multiple Sclerosis: HLA and Non-HLA Effects.
Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats.
Amiloride HCl
Valproic acid ameliorates inflammation in experimental autoimmune encephalomyelitis rats.
Multiparametric MRI correlates of sensorimotor function in the spinal cord in multiple sclerosis.
Axonal conduction and injury in multiple sclerosis: the role of sodium channels.
Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial.
Comparing the biological impact of glatiramer acetate with the biological impact of a generic.
Therapeutic effects of novel sphingosine-1-phosphate receptor agonist W-061 in murine DSS colitis.
Axonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions.
Teva Announces U.S. Supreme Court Will Hear Its Appeal on COPAXONE(R) Patent
Pregnancy outcomes in female patients and partners of male patients in the teriflunomide clinical development program.
Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects.
Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally.
Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
Demyelination affects temporal aspects of perception: An optic neuritis study.
Chondroitin sulfate proteoglycans in the nervous system: inhibitors to repair.
Evaluating more naturalistic outcome measures: A 1-year smartphone study in multiple sclerosis.
RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.
Increase in NF-κB-sensitive miRNA-146a and miRNA-155 in multiple sclerosis (MS) and pro-inflammatory neurodegeneration.

Pages